Bendamustine Hydrochloride Patent Expiration
Bendamustine Hydrochloride was first introduced by Cephalon Inc
Bendamustine Hydrochloride Patents
Given below is the list of patents protecting Bendamustine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Belrapzo | US10010533 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US11103483 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US11844783 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US11872214 | Formulations of Bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US8609707 | Formulations of bendamustine | Aug 11, 2031 | Eagle Pharms |
| Belrapzo | US8791270 | Bendamustine pharmaceutical compositions | Jan 12, 2026 | Eagle Pharms |
| Belrapzo | US9265831 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US9572796 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US9572797 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US10010533 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US10052385 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US11103483 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US11844783 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US11872214 | Formulations of Bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US8609707 | Formulations of bendamustine | Aug 11, 2031 | Eagle Pharms |
| Bendeka | US8791270 | Bendamustine pharmaceutical compositions | Jan 12, 2026 | Eagle Pharms |
| Bendeka |
US8791270 (Pediatric) | Bendamustine pharmaceutical compositions | Jul 12, 2026 | Eagle Pharms |
| Bendeka | US9000021 | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9034908 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9144568 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9265831 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US9572796 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US9572797 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US9572887 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9579384 | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9597397 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9597398 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9597399 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Treanda | US8344006 | Liquid formulations of bendamustine | Sep 23, 2029 | Cephalon |
| Treanda |
US8344006 (Pediatric) | Liquid formulations of bendamustine | Mar 23, 2030 | Cephalon |
| Treanda | US8436190 | Bendamustine pharmaceutical compositions | Oct 26, 2030 | Cephalon |
| Treanda |
US8436190 (Pediatric) | Bendamustine pharmaceutical compositions | Apr 26, 2031 | Cephalon |
| Treanda | US8445524 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Treanda |
US8445524 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Treanda | US8609863 | Bendamustine pharmaceutical compositions | Jan 12, 2026 | Cephalon |
| Treanda |
US8609863 (Pediatric) | Bendamustine pharmaceutical compositions | Jul 12, 2026 | Cephalon |
| Treanda | US8669279 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Treanda |
US8669279 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Treanda | US8791270 | Bendamustine pharmaceutical compositions | Jan 12, 2026 | Cephalon |
| Treanda |
US8791270 (Pediatric) | Bendamustine pharmaceutical compositions | Jul 12, 2026 | Cephalon |
| Treanda | US8883836 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Treanda |
US8883836 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Treanda | US8895756 | Bendamustine pharmaceutical compositions | Jan 12, 2026 | Cephalon |
| Treanda |
US8895756 (Pediatric) | Bendamustine pharmaceutical compositions | Jul 12, 2026 | Cephalon |
| Treanda | US9533955 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Treanda |
US9533955 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Vivimusta | US11844784 | Stable pharmaceutical compositions of bendamustine | Jul 29, 2042 | Slayback Pharma Llc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bendamustine Hydrochloride's patents.
Latest Legal Activities on Bendamustine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Bendamustine Hydrochloride.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9533955 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jun, 2024 | US8344006 |
| Email Notification | 20 Dec, 2023 | US11844784 |
| Recordation of Patent Grant Mailed | 19 Dec, 2023 | US11844784 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844784 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844784 |
| Patent Issue Date Used in PTA Calculation | 19 Dec, 2023 | US11844784 |
| Recordation of Patent eGrant | 19 Dec, 2023 | US11844784 |
| Email Notification | 30 Nov, 2023 | US11844784 |
| Issue Notification Mailed | 29 Nov, 2023 | US11844784 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Bendamustine Hydrochloride Generics
Several generic applications have been filed for Bendamustine Hydrochloride. The first generic version for Bendamustine Hydrochloride was by Innopharma Licensing Llc and was approved on Mar 24, 2016. And the latest generic version is by Nang Kuang Pharmaceutical Co Ltd and was approved on Jun 7, 2023.
Given below is the list of companies who have filed for Bendamustine Hydrochloride generic.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Dec 7, 2022 |
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Dec 7, 2022 |
2. NANG KUANG PHARM CO
Nang Kuang Pharmaceutical Co Ltd has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Nang Kuang Pharm Co.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Discontinued | IV (INFUSION) | N/A | Jun 7, 2023 |
| 100MG/VIAL | powder | Discontinued | IV (INFUSION) | N/A | Jun 7, 2023 |
3. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Dec 7, 2022 |
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Dec 7, 2022 |
4. INNOPHARMA LICENSING
Innopharma Licensing Llc has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Innopharma Licensing.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Mar 24, 2016 |
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Mar 24, 2016 |
5. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Discontinued | IV (INFUSION) | N/A | Apr 28, 2023 |
| 100MG/VIAL | powder | Discontinued | IV (INFUSION) | N/A | Apr 28, 2023 |
6. HOSPIRA INC
Hospira Inc has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Hospira Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | May 20, 2016 |
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | May 20, 2016 |
7. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Meitheal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Jun 5, 2023 |
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Jun 5, 2023 |
8. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Feb 14, 2023 |
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Feb 14, 2023 |
9. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Jun 5, 2023 |
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Jun 5, 2023 |
10. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Jun 5, 2023 |
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Jun 5, 2023 |
11. GLENMARK PHARMS LTD
Glenmark Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Bendamustine Hydrochloride. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 25MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Mar 24, 2016 |
| 100MG/VIAL | powder | Prescription | IV (INFUSION) | AP | Mar 24, 2016 |